The results of the 2026 adjustment to the National Basic Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List were officially announced on November 14 at the 2026 Innovative Drug High-Quality Development Conference held in Suzhou.
The basic medical insurance list added 107 drugs, of which 51 are Class 1 innovative drugs, a record high. The commercial insurance innovative drug list added 12 drugs, bringing the total to 28. At the same time, two drugs previously included in the commercial insurance innovative drug list were further incorporated into basic medical insurance this year, and CAR-T products also achieved basic medical insurance access for the first time. Looking at this round of adjustments to the medical insurance list, multiple heavyweight innovative drugs achieved "approval and inclusion in the same year." The newly added drugs cover multiple clinical areas including oncology, rare diseases, chronic diseases, mental illness, and pediatric medications, with priority given to innovative drugs with clear clinical benefits and favorable cost-effectiveness evaluations. After the adjustment, the National Medical Insurance Drug List contains a total of 3,331 drugs, including 1,935 Western medicines and 1,396 traditional Chinese patent medicines. Analysts pointed out that as innovative drugs continue to accelerate their entry into medical insurance, the industry's commercialization process is expected to further speed up. The continuous improvement of the dynamic adjustment mechanism for the medical insurance list helps shorten the time for innovative drugs from approval and launch to medical insurance inclusion, improves patient access to medications, and is also expected to further drive the commercialization and volume growth of innovative drugs.
It is worth noting that with the implementation of the medical insurance list, policy support for innovative drugs is further extending from medical insurance access toward hospital provisioning and clinical use. Zhang Ke, Director of the National Healthcare Security Administration, stated that the administration will promote "pre-admission" of new drugs on the list and will carry out "medical, pharmaceutical, insurance, and academic face-to-face" activities in 12 cities to promote the entry of innovative technologies and the latest achievements into hospitals, pharmacies, prescriptions, and classrooms. Meanwhile, the National Health Commission, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration recently jointly issued a notice to further improve the safe and rational provisioning and use of innovative drugs. The notice requires medical institutions at or above the second level to optimize the admission process for innovative drugs and promptly include them in medication lists based on diagnostic and treatment needs. Class 1 new drugs in both lists are not counted toward the "one product, two specifications" rule and are not included in performance monitoring indicators such as the growth rate of average outpatient and inpatient drug costs. For cases involving innovative drugs in the medical insurance list that are not suitable for payment under disease-based payment standards, special case single negotiation can be applied for, which helps further smooth the clinical use and payment channels for innovative drugs.
From an industry trend perspective, the innovative drug sector is gradually entering a development stage that emphasizes both "R&D innovation and commercialization realization." As the linkage mechanism between the medical insurance and commercial insurance "dual lists" is gradually established, and the hospital admission and clinical use processes for innovative drugs continue to be optimized, pharmaceutical companies with strong innovation capabilities, outstanding commercialization abilities, and heavyweight products successively entering their volume growth phase are expected to benefit first. CITIC Securities noted in a research report that national medical insurance negotiations continue to support innovative drugs, with attention on commercialization increments in 2027. As access and renewal rules are further improved, the long-term commercialization expectations for innovative drugs are becoming clearer. At the same time, the synchronized advancement of hospital admission and payment support is expected to accelerate the conversion from list access to prescription volume growth. The firm believes that CAR-T entering basic medical insurance for the first time is expected to improve the accessibility of cell therapy, and that the expansion of ADC medical insurance payment coverage toward more cutting-edge treatment lines and more cancer types is expected to drive domestic sales growth. Sinolink Securities noted in a research report that the dual lists broaden patient payment coverage, and hospital admission policies are expected to accelerate the conversion from list access to in-hospital prescriptions. It is bullish on domestic innovative drug in-hospital volume growth in 2027, with focus on new nationally negotiated products with clear clinical demand and room for further hospital coverage improvement, as well as commercial insurance coverage and actual reimbursement progress for high-value therapies.
Related concept stocks: Innovent Biologics (01801): According to a company announcement, seven of its innovative products were successfully included in the 2026 version of the National Medical Insurance Drug List, covering disease areas with relatively heavy social burden such as oncology (colorectal cancer, renal cancer, hematological tumors), cardiovascular metabolism, and autoimmune diseases. These include products newly included in medical insurance for the first time such as mazdutide, picankibart, and ipilimumab N01, as well as products with newly added indications included in medical insurance such as sintilimab and pirtobrutinib. As of this adjustment, the company's innovative drug portfolio included in the National Medical Insurance Drug List has expanded to 17 products.
Sunshine Pharmaceutical (06887): The company's independently developed sodium-glucose transport protein 2 inhibitor (SGLT-2 inhibitor), the Class 1 innovative drug ologliptin capsules (trade name: Dongzean®), was successfully included in the 2026 version of the National Medical Insurance Drug List. The product was approved for launch in January 2026 and can be used as monotherapy or in combination with metformin to improve glycemic control in adult patients with type 2 diabetes, achieving "approval and inclusion in the same year" in the medical insurance list.
Henlius (02696): The company's Hansizhuang (serplulimab injection) was included in the 2026 version of the National Medical Insurance Drug List for the first time, covering all indications approved and launched in mainland China; Fotonin (fruquintinib citrate capsules) had a second indication newly included in the National Medical Insurance Drug List.
JW Therapeutics-B (02126): The company's core product Breyanzi (relma-cel injection) was officially included in the 2026 version of the National Basic Medical Insurance Drug List, covering three indications: large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. It is worth noting that Breyanzi is the only CAR-T therapy product included in the National Basic Medical Insurance Drug List in this adjustment, marking an important breakthrough for CAR-T in achieving basic medical insurance access.
Comments